Actively Recruiting
MYeloma Resistance And Clonal Evolution
Led by Nantes University Hospital · Updated on 2025-07-14
1400
Participants Needed
2
Research Sites
1565 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
CONDITIONS
Official Title
MYeloma Resistance And Clonal Evolution
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014)
- Patient having consented to participate in the study and his/her biocollection
- Patient affiliated to or benefiting from a social security scheme or similar
You will not qualify if you...
- Minors
- Major under guardianship or curatorship
- Protected persons
- Pregnant or breast-feeding women
- Persons benefiting from the AME
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
La Roche sur Yon Hospital Departmental
La Roche-sur-Yon, France, 85000
Actively Recruiting
2
Nantes University Hospital
Nantes, France, 44093
Actively Recruiting
Research Team
C
Cyrille TOUZEAU, PU
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here